HC Wainwright Forecasts Nicox’s Q3 Earnings (OTCMKTS:NICXF)

Nicox SA (OTCMKTS:NICXF) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Nicox in a report issued on Friday, June 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.09 per share for the quarter, down from their previous estimate of $0.11. The consensus estimate for Nicox’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Nicox’s Q1 2027 earnings at ($0.02) EPS, Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.22 EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at $0.14 EPS.

Nicox Stock Performance

Shares of Nicox stock opened at $0.30 on Monday. The stock’s 50-day simple moving average is $0.30 and its 200-day simple moving average is $0.30. Nicox has a 52 week low of $0.25 and a 52 week high of $0.30.

Nicox Company Profile

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.